Consumer StaplesNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 2030763WGRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $23.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

WGRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Wellgistics Health, Inc. (WGRX), a Consumer Staples sector company. WGRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $23.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Wellgistics Health, Inc. reports quarterly revenue of $1.6M, net income of $-7.7M, free cash flow of $-3.4M. Top institutional holders of WGRX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. WGRX trades on the Nasdaq exchange and files with the SEC under CIK 2030763. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WGRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Wellgistics Health, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$1.6M

Net Income

Q1 2026

$-7.7M

Free Cash Flow

Q1 2026

$-3.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+28.7% YoY
$23.3MFY 2025
FY22 FY23 FY24 $18.1MFY25 $23.3M

Net Income

-1377.1% YoY
$-101.3MFY 2025
FY22 FY23 $-2.9MFY24 $-6.9MFY25 $-101.3M

Operating Income

-1425.6% YoY
$-93.7MFY 2025
FY22 FY23 $-2.9MFY24 $-6.1MFY25 $-93.7M

EPS (Diluted)

-853.3% YoY
$-1.43FY 2025
FY22 FY23 $-0.06FY24 $-0.15FY25 $-1.43

Total Assets

-46.9% YoY
$30.5MFY 2025
FY22 FY23 $338.4KFY24 $57.3MFY25 $30.5M

Total Debt

-26.5% YoY
$34.4MFY 2025
FY22 FY23 $350.0KFY24 $46.8MFY25 $34.4M

Op. Cash Flow

-786.1% YoY
$-10.9MFY 2025
FY22 FY23 $-349.1KFY24 $-1.2MFY25 $-10.9M

AI Insight: WGRX Ratio Trends

Wellgistics faced severe profitability collapse in Q2 2025, with ROIC plunging to -58.9% and negative margins across the board, though leverage fell sharply in Q3 2025.

Q2 2025 saw operating margin of -70.6% and NPM of -85.6%, indicating substantial operating losses during that quarter.

Debt-to-equity spiked to 40.28x in Q2 2025 before contracting to 5.46x by Q3 2025, suggesting deleveraging or capital restructuring.

Q1 2026 ROIC remained deeply negative at -86.3%, the worst return on invested capital in the visible data.

Persistent negative ROIC through Q1 2026 indicates ongoing value destruction; need clarity on path to profitability.

Extreme leverage spike in Q2 2025 (40.28x D/E) warrants investigation into debt structure and covenant compliance.

Get alerted when WGRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Wellgistics Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of WGRX

Put WGRX on your watchlist

Track score changes the day Wellgistics Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is WGRX a good stock to buy?

13F Pro's AI-powered analysis of Wellgistics Health, Inc. (WGRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WGRX are available on the WGRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own WGRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WGRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Wellgistics Health, Inc.'s investment landscape.